AR014969A1 - FORMULATION CONTAINING AT LEAST ONE LATE PROTEIN (PROTEIN L) OF ONE OR MORE PAPILOMAVIRUS AND / OR AT LEAST ONE EARLY PROTEIN (PROTEIN E) ONE OR MORE PAPILOMAVIRUS, PROCEDURE FOR THE PREPARATION OF THE FORMULATION MENTIONED AS WELL AS ITS USE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

FORMULATION CONTAINING AT LEAST ONE LATE PROTEIN (PROTEIN L) OF ONE OR MORE PAPILOMAVIRUS AND / OR AT LEAST ONE EARLY PROTEIN (PROTEIN E) ONE OR MORE PAPILOMAVIRUS, PROCEDURE FOR THE PREPARATION OF THE FORMULATION MENTIONED AS WELL AS ITS USE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR014969A1
AR014969A1 ARP990101311A ARP990101311A AR014969A1 AR 014969 A1 AR014969 A1 AR 014969A1 AR P990101311 A ARP990101311 A AR P990101311A AR P990101311 A ARP990101311 A AR P990101311A AR 014969 A1 AR014969 A1 AR 014969A1
Authority
AR
Argentina
Prior art keywords
protein
papilomavirus
formulation
well
procedure
Prior art date
Application number
ARP990101311A
Other languages
Spanish (es)
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag filed Critical Medigene Ag
Publication of AR014969A1 publication Critical patent/AR014969A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Formulacion que contiene por lo menos una proteína tardía (Proteína L) de uno o más papilomavirus y/o por lo menos una proteína temprana (Proteína E) deuno o más papilomavirus y de aproximadamente 0,3 a aproximadamente 4M, preferentementede aproximadamente 0,4 a aproximadamente 2,5 a 3M, en especialde aproximadamente 0,4 - 0,5 a aproximadamente 1 - 2M, en particular de aproximadamente 7,3 a 7,45, preferentemente igual a 7,4, como eventualmentetambién las adecuadas sustanciasaditivas y/o auxiliares, adecuadas; procedimiento para la preparacion de la formulacion mencionada así como suutilizacion para la manufactura de un medicamento o reactivo de diagnostico.Formulation containing at least one late protein (Protein L) of one or more papillomavirus and / or at least one early protein (Protein E) of one or more papillomavirus and about 0.3 to about 4M, preferably about 0.4 at about 2.5 to 3M, especially about 0.4-0.5 to about 1-2M, in particular about 7.3 to 7.45, preferably equal to 7.4, as well as suitable additives and / or or auxiliary, adequate; procedure for the preparation of the aforementioned formulation as well as its use for the manufacture of a medicament or diagnostic reagent.

ARP990101311A 1998-03-24 1999-03-24 FORMULATION CONTAINING AT LEAST ONE LATE PROTEIN (PROTEIN L) OF ONE OR MORE PAPILOMAVIRUS AND / OR AT LEAST ONE EARLY PROTEIN (PROTEIN E) ONE OR MORE PAPILOMAVIRUS, PROCEDURE FOR THE PREPARATION OF THE FORMULATION MENTIONED AS WELL AS ITS USE MANUFACTURE OF A MEDICINAL PRODUCT AR014969A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19812940A DE19812940A1 (en) 1998-03-24 1998-03-24 Formulation with papillomavirus-specific protein, its production and use

Publications (1)

Publication Number Publication Date
AR014969A1 true AR014969A1 (en) 2001-04-11

Family

ID=7862147

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101311A AR014969A1 (en) 1998-03-24 1999-03-24 FORMULATION CONTAINING AT LEAST ONE LATE PROTEIN (PROTEIN L) OF ONE OR MORE PAPILOMAVIRUS AND / OR AT LEAST ONE EARLY PROTEIN (PROTEIN E) ONE OR MORE PAPILOMAVIRUS, PROCEDURE FOR THE PREPARATION OF THE FORMULATION MENTIONED AS WELL AS ITS USE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (8)

Country Link
EP (1) EP1066321A2 (en)
JP (1) JP2002507625A (en)
AR (1) AR014969A1 (en)
AU (1) AU3598999A (en)
CA (1) CA2323526A1 (en)
DE (1) DE19812940A1 (en)
MX (1) MXPA00009283A (en)
WO (1) WO1999048917A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213299A1 (en) * 2000-12-08 2002-06-12 Leids Universitair Medisch Centrum Immunogenic epitopes of human papilloma virus and uses thereof
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1355925A2 (en) * 2000-12-08 2003-10-29 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
SE9001705D0 (en) * 1990-05-11 1990-05-11 Medscand Ab SET FOR DIAGNOSTICS OF VIRUS BREAKING TUMORS BY IMMUNOASSAY
DK0809700T3 (en) * 1994-10-07 2006-09-18 Univ Loyola Chicago Papillomavirus-like particles, fusion proteins, and their method of preparation
DE4447664C2 (en) * 1994-10-07 1999-04-15 Lutz Prof Dr Gissmann Recombinant papilloma virus-like particles contg. L1 or L2 proteins

Also Published As

Publication number Publication date
EP1066321A2 (en) 2001-01-10
AU3598999A (en) 1999-10-18
JP2002507625A (en) 2002-03-12
DE19812940A1 (en) 1999-10-07
WO1999048917A2 (en) 1999-09-30
MXPA00009283A (en) 2002-12-13
WO1999048917A3 (en) 1999-12-09
CA2323526A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
AR034881A1 (en) INSECTICIDE MIX
BRPI0111220B1 (en) drug conjugates with ethylenedicistein (ec)
DE69941429D1 (en) 1-DEOXY-GALACTONO-JIRIMYCIN DERIVATIVES FOR THE USE OF THE TREATMENT OF LYSOSOMAL MEMBERSHIPS BY INCREASING LYSOSOMAL ALPHA GALACTOSIDASE A
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
PT785948E (en) ANALYSIS OF THE KERATINOCYTE GROWTH FACTOR
CO4290432A1 (en) NEW DERIVATIVES OF PIRAZINACARBOXAMIDA, ITS PREPARATION AND ITS USE IN MEDICINES.
DE69904922D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOL DEPENDENCY CONTAINING OPIOID ANTAGONISTS WITH NMDA RECEPTOR COMPLEX MODULATORS
ES2157886T3 (en) TENSIOACTIVE COMPOSITIONS AND PROCEDURES.
ATE308328T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CLINDAMYCIN AND CLOTRIMAZOLE, FOR THE TREATMENT OF VAGINAL INFECTIONS
MX9704050A (en) New dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals.
HUP0105134A2 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
TR200101970T2 (en) The use of substituted 4-biarylbutyric and 5-biarylpentanoic acid t revs as matrix metalloprotease inhibitors in the treatment of respiratory diseases
IL139318A (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
DE69527366T2 (en) ENZYMATIC COMPOSITION FOR CLINICAL EXAMINATION
DE69133077D1 (en) Preparation of pharmaceutical compositions containing ST1435 for topical use
AR014969A1 (en) FORMULATION CONTAINING AT LEAST ONE LATE PROTEIN (PROTEIN L) OF ONE OR MORE PAPILOMAVIRUS AND / OR AT LEAST ONE EARLY PROTEIN (PROTEIN E) ONE OR MORE PAPILOMAVIRUS, PROCEDURE FOR THE PREPARATION OF THE FORMULATION MENTIONED AS WELL AS ITS USE MANUFACTURE OF A MEDICINAL PRODUCT
AR004093A1 (en) THE USE OF A PROTEIN DERIVED FROM A MAMMALIAN CHEMIOQUINE AND A USEFUL MEDICINAL PRODUCT TO MOBILIZE HEMATOPOIETIC STEM CELLS.
AR020832A1 (en) PROCEDURE FOR THE PREPARATION OF A HIGH PURITY COMPOSITION OF (7ALFA, 17ALFA) -17-HIDROXI-7-METIL-19-NOR-17-PREGN-5- (10) -EN-20-IN-3-ONA
DE69612056D1 (en) TERPEN DERIVATIVES (SARCODICTYINE) AS AN ANTICRECELLENT
ES2140672T3 (en) REPLACED BICYCLE COMPOUNDS, MERGED AND BRIDGES USED AS THERAPEUTIC AGENTS.
DE69711588D1 (en) PHARMACEUTICAL PREPARATION CONTAINING NIMESULIDE FOR TOPICAL USE
DE69804766T2 (en) ISOFLAVON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
AR030647A1 (en) PHARMACEUTICAL COMPOSITION WITH SPECIFIC WATER ACTIVITY
DE3865642D1 (en) PHARMACEUTICAL PREPARATION FOR CHOLELITHOLYSIS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure